National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Brentuximab vedotin (Adcetris®) for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. This is a license extension.


NCPE Assessment Process Complete
Rapid review commissioned 07/02/2018
Rapid review completed 06/03/2018
Rapid Review outcome Full pharmacoeconomic assessment recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.